Charles Mullighan, MD, delves into the genomic classification of Acute Lymphoblastic Leukemia (ALL) and its diagnostic approaches. He covers three main areas: B-cell ALL (BOL), implications for risk stratification and diagnosis, and insights into the classification of T-cell ALL (TOL).
After a decade of genomic research, Dr. Mullighan discusses the significant progress made in the genomic classification of BOL. Studies with thousands of patients, including RNA sequencing, have identified around twenty-three subtypes of BOL, each associated with unique clinical features, minimal residual disease (MRD), and outcomes. This has led to the exploration of integrating these subtypes into clinical practice.